Dementia Diagnosis and Management

Assessment Approach

• A comprehensive, multi-dimensional assessment approach using validated cognitive screening tools, informant reports, functional evaluations, and appropriate neuroimaging is essential for accurate dementia diagnosis and management to improve mortality and quality of life outcomes, as recommended by the Alzheimer's Association and the American Academy of Neurology 1, 2

Cognitive Assessment

• The American Academy of Neurology recommends using the Mini-Cog, 5-minute version of MoCA, and GP Assessment of Cognition (GPCOG) as first-line rapid screening tools for dementia diagnosis, with MoCA preferred for mild cognitive impairment detection and MMSE widely used but less sensitive for mild impairment 1
• The following screening tools can be used:

3

Informant Reports and Functional Assessment

• Obtaining information from a reliable informant is crucial for accurate diagnosis, using tools such as Everyday Cognition (ECog), Ascertain Dementia 8 (AD-8) questionnaire, and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) 1
• Functional assessment tools such as Pfeffer Functional Activities Questionnaire (FAQ), Disability Assessment for Dementia (DAD), and Lawton-Brody IADL are recommended 1

Neuroimaging and Laboratory Tests

• Anatomical neuroimaging (MRI preferred, CT if MRI contraindicated) is recommended in most situations, particularly with onset of cognitive symptoms within past 2 years, unexpected decline in cognition/function in known dementia, recent significant head trauma, or unexplained neurological manifestations 1, 2, 4, 5, 6
• Basic laboratory tests, including CBC, comprehensive metabolic panel, TSH, free T4, vitamin B12 level, folate level, glucose level, ESR, and CRP, should be performed to rule out underlying medical conditions, as recommended by internal medicine guidelines and the Alzheimer's Association 2, 4
• The following laboratory tests are recommended as part of a comprehensive evaluation:

4

Behavioral and Psychological Assessment

• The Neuropsychiatric Inventory-Questionnaire (NPI-Q) and Mild Behavioral Impairment Checklist (MBI-C) are recommended for behavioral and psychological assessment, with monitoring for behavioral and psychological symptoms of dementia (BPSD) using NPI-Q or similar tools 1

Caregiver Burden and Prevention

• Assess caregiver burden using structured scales such as Zarit Burden Interview, and provide information on WHO recommendations for dementia prevention 1
• Cognitive training/rehabilitation, physical activity, and Mediterranean diet are non-pharmacological interventions for dementia management, as recommended by the American Academy of Neurology and the Alzheimer's Association 1, 7

Risk Factors and Pharmacological Interventions

• The following risk factors are associated with cognitive impairment:

8, 9

• Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, can improve global cognitive function, with donepezil starting at 5mg daily and may increase to 10mg daily after 4-6 weeks, as recommended by the American College of Physicians and the American Academy of Neurology 10
• Memantine may be added for moderate cognitive impairment, and can be used alone or in combination with a cholinesterase inhibitor, as recommended by the American College of Physicians and the American Academy of Neurology 10

Follow-up and Monitoring

• Regular follow-up every 6-12 months (more frequent for behavioral symptoms) is recommended, assessing all domains (cognition, function, behavior, caregiver burden) at least annually, with evaluation of the effectiveness of interventions and monitoring cognitive, functional, and behavioral changes every 3-6 months 1, 7